1442. Deputy Ken O'Flynn asked the Minister for Health when the HSE first identified the need for dedicated SCAN nurses in the HSE Mid-West region. [39819/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
1,428 questions match, newest first.
1443. Deputy Ken O'Flynn asked the Minister for Health whether the HSE conducted any benchmarking comparing SCAN coverage across HSE regions prior to approving funding for two SCAN nurses in the Mid-West. [39820/26]
1444. Deputy Ken O'Flynn asked the Minister for Health whether any adverse incident reviews, crisis response reviews, or emergency department escalation reviews referenced the absence of SCAN services in the Mid-West. [39821/26]
1445. Deputy Ken O'Flynn asked the Minister for Health how many dedicated SCAN nurses are currently operating in each HSE region. [39822/26]
1446. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has established recommended staffing ratios or population benchmarks for SCAN services nationally. [39823/26]
1447. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE considers the provision of only two SCAN nurses sufficient for the Mid West population and crisis demand profile. [39824/26]
1448. Deputy Ken O'Flynn asked the Minister for Health when the two approved SCAN nurse posts for the Mid-West are expected to become operational. [39825/26]
1449. Deputy Ken O'Flynn asked the Minister for Health whether the posts have been advertised, filled, or remain vacant. [39826/26]
1450. Deputy Ken O'Flynn asked the Minister for Health whether any business case or service development proposal supporting the Mid-West SCAN expansion will be published. [39827/26]
1451. Deputy Ken O'Flynn asked the Minister for Health whether the HSE formally reviewed reimbursement, managed access, or pricing decisions relating to omaveloxolone (skyclarys) in France, Germany, Italy, Spain, Belgium, the Netherlands or the United Kingdom as part of the Irish reimbursement assessment process; and if she will provide details of any such comparative analysis undertaken. [39831/26]
1452. Deputy Ken O'Flynn asked the Minister for Health whether the National Centre for Pharmacoeconomics considered any international managed access agreements, risk-sharing agreements, conditional reimbursement models or outcomes-based reimbursement arrangements in respect of omaveloxolone (Skyclarys); and if she will provide details of the jurisdictions and models reviewed. [39832/26]
1453. Deputy Ken O'Flynn asked the Minister for Health whether any orphan-drug specific weighting, modified cost-effectiveness threshold, severity adjustment or rare disease reimbursement framework was applied in the assessment of omaveloxolone (skyclarys); and if she will make a statement on the matter. [39833/26]
1454. Deputy Ken O'Flynn asked the Minister for Health whether the assessment of omaveloxolone (skyclarys) included analysis of indirect societal costs associated with Friedreich's ataxia, including disability supports, caregiver burden, loss of educational participation, workforce impacts and long-term health service utilisation; and if she will provide details of the methodology used. [39834/26]
1455. Deputy Ken O'Flynn asked the Minister for Health whether Ireland currently operates a distinct reimbursement or pharmacoeconomic assessment pathway for orphan medicines or ultra-rare disease therapies; if so, to provide details of the framework and criteria applied; and if she will make a statement on the matter. [39835/26]
1456. Deputy Ken O'Flynn asked the Minister for Health the number of orphan or ultra-rare disease medicines which received a negative reimbursement recommendation from the National Centre for Pharmacoeconomics in each year since 2020; and the number subsequently approved for reimbursement following commercial negotiation or further review. [39836/26]
1457. Deputy Ken O'Flynn asked the Minister for Health the average period between European Medicines Agency authorisation and final reimbursement decision in Ireland for orphan medicines in each year since 2020; and how this compares with the EU average where such data is available. [39837/26]
1458. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has undertaken any comparative analysis of Ireland's orphan drug reimbursement timelines and approval rates against comparable European jurisdictions; and if she will provide details of any such analysis. [39838/26]
1459. Deputy Ken O'Flynn asked the Minister for Health whether patient organisations or rare disease advocacy groups were consulted or invited to make submissions during the reimbursement assessment process for omaveloxolone (skyclarys); and if she will provide details of the process involved. [39839/26]
1460. Deputy Ken O'Flynn asked the Minister for Health whether the HSE Drugs Group considered the progressive and degenerative nature of Friedreich's ataxia, including irreversible disease progression during reimbursement delays, in its consideration of omaveloxolone (Skyclarys); and if she will make a statement on the matter. [39840/26]
1461. Deputy Claire Kerrane asked the Minister for Health the position regarding access to a drug (details supplied) for people suffering with Duchenne muscular dystrophy; when this drug will be available for children and young people in Ireland; and if she will make a statement on the matter. [39872/26]
1462. Deputy Conor Sheehan asked the Minister for Health the specific timeline for the completion of the comprehensive scoping exercise regarding the preferred model for a dedicated Sexual Assault Treatment Unit (SATU) in the midwest region; the exact metrics, data thresholds and clinical criteria that constitute the “demonstrated local need” required to greenlight the facility; and if she will make a statement on th…
1463. Deputy Roderic O'Gorman asked the Minister for Health the number of persons in County Tipperary waiting for home support hours; the number approved but not yet in receipt of hours; the average waiting time; and if she will make a statement on the matter. [39932/26]
1464. Deputy Colm Burke asked the Minister for Health the supports available through the HSE QUIT smoking cessation service for people seeking to stop using nicotine products; if these supports include smoking cessation supports for users of e-cigarettes/vapes and oral nicotine products such as nicotine pouches; and if she will make a statement on the matter. [39945/26]
1465. Deputy Maurice Quinlivan asked the Minister for Health her views on a matter (details supplied); and if she will make a statement on the matter. [39966/26]
1466. Deputy Richard Boyd Barrett asked the Minister for Health if she will review the case of a person (details supplied); and if she will make a statement on the matter. [39994/26]